Scholarlink

Objectives <p>To evaluate whether tocotrienol-rich vitamin E improves nerve-conduction parameters and symptoms in diabetic peripheral neuropathy (DPN).</p> Methods <p>Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA 2020 (PROSPERO CRD420250653145), we searched the PubMed, Web of Science, Scopus, and Embase databases up until 20 March 2025, for parallel-group randomized controlled trials (RCTs) of oral vitamin E in adults (≥ 18 years) with electrophysiologically confirmed DPN. Two independent reviewers performed screening, extraction, and the revised Cochrane Risk of Bias tool version 2.0 (RoB 2.0). Random-effects meta-analyses were conducted using the mean differences (MD) with 95% confidence intervals (CI).</p> Results <p>Five RCTs (<i>n</i> = 660) met the criteria. Tocotrienol-rich vitamin E increased sural sensory nerve-conduction velocity (NCV) by 1.77&#xa0;m s⁻¹ (0.80–2.74) and median sensory NCV by 1.53&#xa0;m s⁻¹ (0.44–2.63); tibial motor NCV rose 1.47&#xa0;m s⁻¹ (0.36–2.58) versus placebo. Nerve-action-potential amplitudes and glycated hemoglobin A1c (HbA₁c) were unchanged (MD − 0.06%, − 0.18–0.06). Adverse-event rates were similar between groups. Two trials had a low risk of bias; one presented some concerns.</p> Discussion <p>Vitamin E yielded selective NCV gains without amplitude change, suggesting preservation or remyelination of sensory fibers rather than axonal regeneration. The absence of glycemic effects indicates neuroprotection independent of glucose control, positioning vitamin E as a potential adjunct—not substitute—to antidiabetic therapy. Heterogeneity in isoform, dose, and treatment duration (≤ 12 months) and modest sample sizes limit certainty. Larger, longer trials incorporating functional outcomes (pain, gait, and quality of life) are required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of vitamin E in the treatment of diabetic neuropathy: systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年1月13日

查看全文
  • Raghad Alhajaji,
  • Ahmed A. Hassan,
  • Manar Ahmad Al-Harahsheh,
  • Reem Rabie Saber,
  • Marina Amgad Soliman,
  • Amr Mahmoud Alam Eldin,
  • Engy Sherif Sabry,
  • Mena Ayman Elgendy,
  • Ganna Hatem Farouk,
  • Walaa Mokhtar El-basiony,
  • Heba Hendi Goda,
  • Mohamed Saad Sayed

摘要

Objectives

To evaluate whether tocotrienol-rich vitamin E improves nerve-conduction parameters and symptoms in diabetic peripheral neuropathy (DPN).

Methods

Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA 2020 (PROSPERO CRD420250653145), we searched the PubMed, Web of Science, Scopus, and Embase databases up until 20 March 2025, for parallel-group randomized controlled trials (RCTs) of oral vitamin E in adults (≥ 18 years) with electrophysiologically confirmed DPN. Two independent reviewers performed screening, extraction, and the revised Cochrane Risk of Bias tool version 2.0 (RoB 2.0). Random-effects meta-analyses were conducted using the mean differences (MD) with 95% confidence intervals (CI).

Results

Five RCTs (n = 660) met the criteria. Tocotrienol-rich vitamin E increased sural sensory nerve-conduction velocity (NCV) by 1.77 m s⁻¹ (0.80–2.74) and median sensory NCV by 1.53 m s⁻¹ (0.44–2.63); tibial motor NCV rose 1.47 m s⁻¹ (0.36–2.58) versus placebo. Nerve-action-potential amplitudes and glycated hemoglobin A1c (HbA₁c) were unchanged (MD − 0.06%, − 0.18–0.06). Adverse-event rates were similar between groups. Two trials had a low risk of bias; one presented some concerns.

Discussion

Vitamin E yielded selective NCV gains without amplitude change, suggesting preservation or remyelination of sensory fibers rather than axonal regeneration. The absence of glycemic effects indicates neuroprotection independent of glucose control, positioning vitamin E as a potential adjunct—not substitute—to antidiabetic therapy. Heterogeneity in isoform, dose, and treatment duration (≤ 12 months) and modest sample sizes limit certainty. Larger, longer trials incorporating functional outcomes (pain, gait, and quality of life) are required.